Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
| Revenue (TTM) | $47.35B |
| Gross Profit (TTM) | $19.54B |
| EBITDA | $12.13B |
| Operating Margin | 20.20% |
| Return on Equity | 13.40% |
| Return on Assets | 5.19% |
| Revenue/Share (TTM) | $127.37 |
| Book Value | $147.80 |
| Price-to-Book | 4.58 |
| Price-to-Sales (TTM) | 5.44 |
| EV/Revenue | 6.04 |
| EV/EBITDA | 22.81 |
| Quarterly Earnings Growth (YoY) | 8.70% |
| Quarterly Revenue Growth (YoY) | 9.10% |
| Shares Outstanding | $370.52M |
| Float | $369.60M |
| % Insiders | 0.13% |
| % Institutions | 93.11% |
Volatility is currently expanding
The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier Global and Builders FirstSource.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduces the Thermo Scientific AmpSure Universal SYBR Green and Probe Master Mixes. Designed for everyday applications, the mixes support reliable, reproducible quantitative PCR (qPCR) performance and offer researchers a value-priced option as labs balance performance with budget.Consistent performance is essential for generating quality data, completing experiments and publishing research. Th.
Jim Cramer just declared the companies that supply drug labs and research instruments the true heirs to the data center trade, and three stocks are already beating the NASDAQ-100 by a wide margin this year.
Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Watson and Verizon. Bottom contributors include Cummins, Applied Materials, Brookfield Renewable, Home Depot and AstraZeneca.
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.
Thermo Fisher Scientific Inc. delivered strong Q3 results, with 6% organic growth, EPS and sales beats, and raised full-year guidance. TMO's growth is driven by robust demand in clinical research, bioproduction, and electron microscopy, supported by recent strategic acquisitions. Operating margin reached 24.5%, aided by divestitures, acquisitions, and ongoing process improvements.
Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue reached $12.14 billion with 6% organic growth.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 1% on Wednesday.
Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript
Thermo Fisher beats Q3 earnings and revenue estimates, with double-digit profit growth and wider margins, yet shares fall 4.1% in pre-market trading.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TMO and any ticker you trade — then tracks every position and per-strategy win rate.
